.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Baxter
Julphar
US Department of Justice
Queensland Health
Federal Trade Commission
QuintilesIMS
McKesson
Harvard Business School

Generated: December 16, 2017

DrugPatentWatch Database Preview

OPANA Drug Profile

« Back to Dashboard

Which patents cover Opana, and when can generic versions of Opana launch?

Opana is a drug marketed by Endo Pharms and is included in four NDAs. There are ten patents protecting this drug and six Paragraph IV challenges.

The generic ingredient in OPANA is oxymorphone hydrochloride. There are nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxymorphone hydrochloride profile page.
Drug patent expirations by year for OPANA

Pharmacology for OPANA

Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for OPANA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-007Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-004Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-003Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-005Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-006Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-003Jun 22, 2006DISCNNoNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-005Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-007Feb 29, 2008DISCNNoNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-006Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-003Dec 9, 2011DISCNYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for OPANA

Drugname Dosage Strength RLD Submissiondate
oxymorphone hydrochlorideExtended-release Tablets7.5 mg, 10 mg, and 15 mgOpana ER (NDA 201655)3/23/2012
oxymorphone hydrochlorideExtended-release Tablets20 mg, 30 mg, 40 mgOpana ER (NDA 201655)4/3/2012
oxymorphone hydrochlorideExtended-release Tablets5 mgOpana ER (NDA 201655)3/26/2012
oxymorphone hydrochlorideExtended-release Tablets30 mgOpana ER6/12/2008
oxymorphone hydrochlorideExtended-release Tablets7.5 mg and 15 mgOpana ER5/29/2008
oxymorphone hydrochlorideExtended-release Tablets5 mg, 10 mg, 20 mg and 40 mgOpana ER11/23/2007

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Citi
Fish and Richardson
Healthtrust
Moodys
Dow
QuintilesIMS
Covington
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot